Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

  title={Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.},
  author={B. Druker and M. Talpaz and D. Resta and B. Peng and E. Buchdunger and J. Ford and N. Lydon and H. Kantarjian and R. Capdeville and S. Ohno-Jones and C. Sawyers},
  journal={The New England journal of medicine},
  volume={344 14},
  • B. Druker, M. Talpaz, +8 authors C. Sawyers
  • Published 2001
  • Medicine
  • The New England journal of medicine
  • BACKGROUND BCR-ABL is a constitutively activated tyrosine kinase that causes chronic myeloid leukemia (CML). Since tyrosine kinase activity is essential to the transforming function of BCR-ABL, an inhibitor of the kinase could be an effective treatment for CML. METHODS We conducted a phase 1, dose-escalating trial of STI571 (formerly known as CGP 57148B), a specific inhibitor of the BCR-ABL tyrosine kinase. STI571 was administered orally to 83 patients with CML in the chronic phase in whom… CONTINUE READING
    4,730 Citations

    Paper Mentions

    The proposed study, may significantly contribute to improve healthcare delivery in patients with Chronic Myeloid Leukemia (CML) treated with modern tyrosine kinase inhibitors (TKIs) in… Expand
    ConditionsCancer, Leukemia, Chronic Myeloid
    This pilot clinical trial studies sirolimus, idarubicin, and cytarabine in treating patients with newly diagnosed acute myeloid leukemia. Sirolimus may stop the growth of cancer cells by… Expand
    ConditionsAdult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), (+11 more)
    STI571: targeting BCR-ABL as therapy for CML.
    • 217
    • PDF
    Tyrosine kinase inhibitor as a therapeutic drug for chronic myelogenous leukemia and gastrointestinal stromal tumor.
    • M. Nakajima, W. Toga
    • Chemistry, Medicine
    • Nihon yakurigaku zasshi. Folia pharmacologica Japonica
    • 2003
    • 5
    Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases.
    • 161
    • PDF
    Reduced Dose Imatinib Mesylate Therapy for Chronic Myeloid Leukemia
    • 2
    • Highly Influenced
    Imatinib in Chronic Myeloid Leukemia: an Overview
    • T. Sacha
    • Medicine
    • Mediterranean journal of hematology and infectious diseases
    • 2014
    • 45
    • PDF


    Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.
    • 844
    • PDF
    Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.
    • 491
    • PDF